CJC-1295 lab monitoring
Which blood work to run before, during and after a CJC-1295 (with DAC) cycle, and what the research can and can't tell you about the results. CJC-1295 is the one GH-stack peptide with human IGF-1 data: in two trials in healthy adults, single and repeated injections raised IGF-1 for days to weeks (PMID 16352683). Those trials used doses well above what people commonly self-administer, so they set a direction, not a target number.
When to test
1. Baseline (before you start)
| Marker | Why test it | Standard range |
|---|---|---|
| IGF-1 Insulin-like growth factor 1 | The marker CJC-1295 is meant to move. In the trials, IGF-1 rose after every dose level studied (PMID 16352683). Your own baseline is what week 4 gets compared against. | Depends on age and sex. Labcorp adult examples: ages 21-25, men 109-353 and women 101-347; ages 41-45, men 84-270 and women 74-239; ages 56-60, men 68-247 and women 60-207 ng/mL Source: Labcorp test 010363 |
| Fasting glucose Fasting plasma glucose | Growth hormone works against insulin (PMID 29025199), so you want to know your starting glucose before you push the GH axis. Fast for at least 8 hours before the draw. | Normal under 100; prediabetes 100-125; diabetes 126 or higher mg/dL Source: American Diabetes Association |
| HbA1c Hemoglobin A1c | A one-off screen for existing blood-sugar problems. It reflects roughly the last 3 months, so it is too slow to show change within an 8-12 week cycle. Fasting glucose is the marker to repeat. | Normal under 5.7%; prediabetes 5.7-6.4%; diabetes 6.5% or higher Source: American Diabetes Association |
| CBC Complete blood count | A standard safety baseline before any injectable peptide, so you have your own reference point if you feel unwell during the cycle. | WBC 4.0-10 k/mcL; hemoglobin 13-17 g/dL men, 11.5-15.5 g/dL women; platelets 150-400 k/mcL Source: Cleveland Clinic |
2. Mid-cycle (week 4)
IGF-1 is expected to rise; compare with baseline at the same lab
| Marker | Why test it |
|---|---|
| IGF-1 Insulin-like growth factor 1 | Compare with your baseline, same lab. IGF-1 peaked 2-3 days after a dose in the trial (PMID 16352683), so draw at the same point in your weekly cycle each time, for example the day before your next injection. |
| Fasting glucose Fasting plasma glucose | The timely check on GH's effect on blood sugar. Same fasting conditions as baseline. |
3. Post-cycle (2-4 weeks after your last dose)
| Marker | Why test it |
|---|---|
| IGF-1 Insulin-like growth factor 1 | Should be heading back toward your baseline once the drug has cleared. |
| Fasting glucose Fasting plasma glucose | Confirms glucose is back where it started. |
Ranges differ between labs. IGF-1 ranges also depend on age, sex and the assay the lab uses, so run every IGF-1 draw at the same lab and read it against the age band printed on your own report. Glucose and HbA1c cut-offs are the American Diabetes Association's diagnostic thresholds. CBC ranges come from Cleveland Clinic.
What to expect
-
IGF-1: expected to rise (baseline to week 4)
In healthy adults, a single injection raised mean IGF-1 1.5- to 3-fold for 9-11 days (PMID 16352683), from pre-dose means of 123-152 ng/mL to mean peaks of 232 ng/mL at 30 µg/kg and 435 ng/mL at 250 µg/kg. With 2-3 weekly or every-other-week injections, IGF-1 stayed above baseline for up to 28 days. IGF-1 went above the age- and sex-adjusted normal range only at 250 µg/kg. The lowest dose studied was 20 µg/kg (about 1.4 mg for a 70 kg adult). The commonly reported community dose of 1,000 mcg a week is about 14 µg/kg for a 70 kg adult, below anything studied, so how much IGF-1 rises at that dose is unknown.
If it doesn't: There is no established target, so don't read a modest rise as failure. But no IGF-1 movement at all from baseline is consistent with an under-dose or a vial problem. Check the certificate of analysis for your batch before you raise the dose.
-
Fasting glucose: may drift up; should stay in range (baseline, week 4, post-cycle)
Growth hormone raises blood sugar by working against insulin (PMID 29025199). In the CJC-1295 trials there were no consistent changes in glucose levels (PMID 16352683), but those lasted 28 and 49 days.
If it doesn't: A move from normal into the prediabetes range (100 or higher) is a reason to stop and talk to a clinician, whatever the source of the vial.
Your labs can't check your vial
Your labs can't check your vial for you. IGF-1 can hint that something is wrong (no rise at all), but a rise doesn't prove you have CJC-1295 with DAC rather than another GHRH analog. Danish customs seizures analysed by forensic chemists contained glycine-modified analogs of ipamorelin and modified GRF 1-29, not the compounds themselves (PMID 30136411), and a German survey of black-market products found peptide hormones among the doping agents seized (PMID 25168622). FDA says compounded CJC-1295 "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to for peptide-related impurities and API characterization." Identity and purity get checked on the product's certificate of analysis, against the testing lab's own record.
What the research doesn't show
- The human data is two small trials in healthy adults aged 21-61 (PMID 16352683): four single-dose groups (30-250 µg/kg) and four repeated-dose groups (20-60 µg/kg) followed for 28 and 49 days. No study has tested an 8-12 week cycle.
- No human study has tested the commonly reported community dose of about 1,000 mcg a week.
- In those trials there were no consistent changes in blood or urine lab values, including glucose and liver tests (PMID 16352683). That doesn't cover longer cycles or higher doses.
- Prolactin and cortisol are not on this panel. Reviews list rises in both as class effects of GH-axis peptides (PMID 42395176), but ipamorelin did not raise either in animal studies (PMID 9849822), and CJC-1295 did not raise them in humans (PMID 16352683). Unexplained breast tenderness or nipple discharge is a reason to see a clinician.
- Banned in sport: the 2026 WADA Prohibited List names CJC-1295 as an example of a GHRH analogue under S2, prohibited at all times. Analogues are covered by the class even when not named.
Sources
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006. PMID 16352683
- Labcorp test 010363: Insulin-like growth factor 1 (IGF-1), age- and sex-specific reference ranges
- American Diabetes Association: Diagnosis (A1C and fasting plasma glucose thresholds)
- Cleveland Clinic: Complete blood count (normal values for adults)
- Kim SH, Park MJ. Effects of growth hormone on glucose metabolism and insulin resistance in human. Ann Pediatr Endocrinol Metab 2017. PMID 29025199
- Gajda PM, et al. Glycine-modified growth hormone secretagogues identified in seized doping material. Drug Test Anal 2019. PMID 30136411
- Krug O, et al. Identification of black market products and potential doping agents in Germany 2010-2013. Eur J Clin Pharmacol 2014. PMID 25168622
- Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. Front Endocrinol 2026. PMID 42395176
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (CJC-1295)
- German Sport University Cologne (WADA-accredited lab): S2 Peptide hormones, growth factors, related substances and mimetics (2026 Prohibited List)
Educational content, not medical advice. Reference ranges differ by lab, so read your results against the range printed on your own report, and have a clinician review anything out of range.